Early diagnosis of human immunodeficiency virus-1 infection in infants with the NucliSens EasyQ assay on dried blood spots

Lilian, Rivka R.; Bhowan, Kapila; Sherman, Gayle

doi:10.1016/j.jcv.2010.02.006

Cited by 21 publications

(21 citation statements)

References 6 publications

(12 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This is consistent with other studies detecting the viral loads in children (4,5,(9)(10)(11). Because of this usually high viral load in children, we recommend that a threshold of 5,000 IU/ml be used to interpret HIV-1 positivity, and we consider that cases below this value should be repeated to avoid false positivity.…”

Section: Discussionsupporting

confidence: 89%

“…Some have been developed in-house, while others are commercial, such as the validated Amplicor technique, which has sensitivity on DBS of 98.2 to 100% and a specificity of 98.6 to 100% (15,16,23). The high sensitivity of plasma HIV RNA quantification techniques now allows their substitution for DNA PCR tests (10,22,28). These techniques could be used also for early infant diagnosis (EID) because most infected children in these areas do not have the opportunity to be diagnosed before the age of 18 months.…”

mentioning

confidence: 99%

See 1 more Smart Citation

RNA versus DNA (NucliSENS EasyQ HIV-1 v1.2 versus Amplicor HIV-1 DNA Test v1.5) for Early Diagnosis of HIV-1 Infection in Infants in Senegal

et al. 2011

View full text Add to dashboard Cite

The objective of this study was to compare the performance of the NucliSENS EasyQ HIV-1 v1.2 platform (bioMérieux, France) to the Amplicor HIV-1 DNA test v1.5 (Roche Molecular Systems, Switzerland) in detecting HIV-1 infection in infants using venipuncture-derived whole blood in tubes and dried blood spots. A total of 149 dried blood spots and 43 EDTA-anticoagulated peripheral blood samples were collected throughout Dakar and other areas in Senegal from infants and children aged 3 weeks to 24 months who were born to HIV-1-infected mothers. Samples were tested using the NucliSENS and Amplicor technologies. The NucliSENS and Amplicor results were 100% concordant using either EDTA-anticoagulated peripheral blood or dried blood spots. Compared to Amplicor, the sensitivity and specificity of the NucliSENS test were 100%. The NucliSENS EasyQ HIV-1 RNA assay performed as well as the Amplicor HIV-1 DNA test in detecting HIV-1 infection in infants. In addition, this platform can give an indication of the viral load baseline. The NucliSENS EasyQ platform is a good alternative for early infant diagnosis of HIV-1 infection.

show abstract

Section: Discussionsupporting

confidence: 89%

mentioning

confidence: 99%

RNA versus DNA (NucliSENS EasyQ HIV-1 v1.2 versus Amplicor HIV-1 DNA Test v1.5) for Early Diagnosis of HIV-1 Infection in Infants in Senegal

et al. 2011

View full text Add to dashboard Cite

show abstract

“…Indeed, DBS offers numerous advantages over conventional whole blood, plasma, or serum sample collection. Furthermore, the procedure is clearly less invasive and cost effective in terms of sample collection, shipment and storage [1][2][3][4]. Due to its easiness, the DBS collection can be performed after a small finger prick in a non-hospital environment with minimal training by technicians or even by patients themselves [5,6].…”

Section: Introductionmentioning

confidence: 99%

Automated system for on-line desorption of dried blood spots applied to LC/MS/MS pharmacokinetic study of flurbiprofen and its metabolite

Déglon

Thomas

Daali

et al. 2011

Journal of Pharmaceutical and Biomedical Analysis

View full text Add to dashboard Cite

This paper illustrates the development of an automated system for the on-line bioanalysis of dried blood spots (on-line DBS). In this way, a prototype was designed for integration into a conventional LC/MS/MS, allowing the successive extraction of 30 DBS toward the analytical system without any sample pretreatment. The developed method was assessed for the DBS analysis of flurbiprofen (FLB) and its metabolite 4-hydroxyflurbiprofen (OH-FLB) in human whole blood (i.e. 5 μL). The automated procedure was fully validated based on international criteria and showed good precision, trueness, and linearity over the expected concentration range (from 10 to 1000 ng/mL and 100 to 10,000 ng/mL for OH-FLB and FLB respectively). Furthermore, the prototype showed good results in terms of recovery and carry-over. Stability of both analytes on filter paper was also investigated and the results suggested that DBS could be stored at ambient temperature for over 1 month. The on-line DBS automated system was then successfully applied to a pharmacokinetic study performed on healthy male volunteers after oral administration of a single 50-mg dose of FLB. Additionally, a comparison between finger capillary DBS and classic venous plasma concentrations was investigated. A good correlation was observed, demonstrating the complementarity of both sampling forms. The automated system described in this article represents an efficient tool for the LC/MS/MS analysis of DBS samples in many bioanalytical applications.

show abstract

“…Finally, dried blood spots have proven to be an ideal specimen type that is easy to obtain in settings where phlebotomy is not feasible or when transport of venipuncture specimens is impractical. They produce accurate results with antigen and antibody immunoassays and nucleic acid tests [75][76][77][78]. However, only suboptimal second-generation IgG-only EIAs, the HIV-1 Western blot, and the indirect immunofluorescence assay are FDA-approved for use with dried blood spot specimens, which severely limits their utility with the updated diagnostic algorithm.…”

Section: The Three-legged Racementioning

confidence: 99%

HIV Testing Updates and Challenges: When Regulatory Caution and Public Health Imperatives Collide

Branson¹

2015

Curr HIV/AIDS Rep

View full text Add to dashboard Cite

Numerous improvements in HIV testing technology led recently to the first revision of recommendations for diagnostic laboratory testing in the USA in 25 years. Developments in HIV testing continue to produce tests that identify HIV infection earlier with faster turnaround times for test results. These play an important role in identifying HIV infection during the highly infectious acute phase, which has implication for both patient management and public health interventions to control the spread of HIV. Access to these developments, however, is often delayed by the regulatory apparatus for approval and oversight of HIV testing in the USA. This article summarizes recent developments in HIV diagnostic testing technology, outlines their implications for clinical management and public health, describes current systems of regulatory oversight for HIV testing in the USA, and proposes alternatives that could expedite access to improved tests as they become available.

show abstract

Early diagnosis of human immunodeficiency virus-1 infection in infants with the NucliSens EasyQ assay on dried blood spots

Cited by 21 publications

References 6 publications

RNA versus DNA (NucliSENS EasyQ HIV-1 v1.2 versus Amplicor HIV-1 DNA Test v1.5) for Early Diagnosis of HIV-1 Infection in Infants in Senegal

RNA versus DNA (NucliSENS EasyQ HIV-1 v1.2 versus Amplicor HIV-1 DNA Test v1.5) for Early Diagnosis of HIV-1 Infection in Infants in Senegal

Automated system for on-line desorption of dried blood spots applied to LC/MS/MS pharmacokinetic study of flurbiprofen and its metabolite

HIV Testing Updates and Challenges: When Regulatory Caution and Public Health Imperatives Collide

Contact Info

Product

Resources

About